MMP11 and breast carcinoma: This complements previous research using immunohistochemistry, such as [24] and [34], or RNA studies: for example, MMP-11 has been identified as part of a distinguishing genomic signature of “metastasis-associated fibroblasts” [48], a genomic signature related to breast cancer progression [49] and a genomic signature associated with the risk of recurrence of tamoxifen-treated, node-negative breast cancer [6].